OHR Pharmaceutical (NASDAQ:OHRP) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.
Shares of NASDAQ OHRP remained flat at $$0.20 during mid-day trading on Thursday. 413,033 shares of the stock traded hands, compared to its average volume of 1,815,922. OHR Pharmaceutical has a 12 month low of $0.15 and a 12 month high of $2.18.
OHR Pharmaceutical (NASDAQ:OHRP) last posted its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.01) earnings per share for the quarter.
About OHR Pharmaceutical
OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Featured Story: What is a bull market?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.